Turning Point Therapeutics (TPTX) Financials

$76.01

$0.00 (0.00%)

As on 07-Sep-2022 09:30EDT

Market cap

$3,806 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

4.8

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-08	Dec-07	Dec-06	Dec-05	Dec-04
Operating Revenue	1.03	30.83	25.00	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	1.03	30.83	0.00	--	--	--
Operating Expenses	345.60	268.83	186.84	77.72	25.64	16.73
Operating Profit (EBIT)	-344.59	-238.00	-161.84	-77.72	-25.64	-16.73
Other Income	--	--	--	--	--	--
Profit before Tax	-342.31	-236.55	-157.29	-72.13	-24.78	-16.59
Provision for Tax	--	--	--	--	0.00	0.00
Profit after Tax (Net Income)	-342.31	-236.55	-157.29	-72.13	-24.79	-16.59
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-342.31	-236.55	-157.29	-72.13	-24.79	-16.59

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-08	Dec-07	Dec-06	Dec-05	Dec-04
Shareholder's Funds	793.02	954.43	1,109.90	404.35	97.51	-24.84
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.89	1.95	2.42	3.82	0.45	66.23
Current Liabilities	49.42	47.09	24.39	14.03	5.32	4.53
Total Liabilities	892.76	1,003.46	1,136.71	422.20	103.28	45.91

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-08	Dec-07	Dec-06	Dec-05	Dec-04
Non-Current Assets	11.67	11.00	6.03	7.26	1.76	0.29
Current Assets	831.67	992.46	1,130.68	414.95	101.52	45.61
Total Assets	892.76	1,003.46	1,136.71	422.20	103.28	45.91
Total Debt*	4.94	5.58	3.82	5.06	--	--
Net Current Assets	782.24	945.37	1,106.29	400.92	96.20	41.09

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-08	Dec-07	Dec-06	Dec-05	Dec-04
Cash From Operating Activities	--	-153.89	-82.79	-57.76	-23.53	-12.64
Cash Flow from Investing Activities	--	5.46	-210.03	-361.08	-0.30	-0.09
Cash from Financing Activities	--	24.00	798.74	366.00	79.83	44.85
Net Cash Inflow / Outflow	--	--	505.91	-52.84	--	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-08	Dec-07	Dec-06	Dec-05	Dec-04
Adjusted EPS ($)	-6.91	-4.83	-3.84	-3.01	-8.26	--
Cash EPS ($)	--	-4.75	-3.78	-2.94	-8.22	--
Adjusted Book Value ($)	--	19.48	27.07	16.85	32.50	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-3.14	-2.02	-2.41	-7.84	--
Free Cash Flow per Share ($)	--	-3.19	-2.05	-2.48	-7.95	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-08	Dec-07	Dec-06	Dec-05	Dec-04
ROCE (%)	--	-22.81	-20.65	-28.46	-68.22	--
ROE (%)	-39.18	-22.92	-20.77	-28.75	-68.22	--
ROA (%)	-33.77	-22.11	-20.18	-27.45	-33.23	--
EBIT Margin (%)	-33,130.60	-767.30	-629.17	--	--	--
Net Margin (%)	-33,130.60	-767.30	-629.17	--	--	--
Cash Profit Margin (%)	-0.01	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-08	Dec-07	Dec-06	Dec-05	Dec-04
Revenue Growth (%)	-98.13	0.23	--	--	--	--
EBIT Growth (%)	-118.23	-50.39	-102.37	-203.14	-53.27	--
Net Profit Growth (%)	-118.23	-50.39	-118.06	-191.03	-49.37	--
EPS Growth (%)	-100.15	-0.26	-0.28	0.64	--	--
Book Value Growth (%)	-27.20	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-08	Dec-07	Dec-06	Dec-05	Dec-04
Price / Earnings	--	-9.88	-31.76	-20.73	--	--
Price / Book Value	4.80	2.45	4.50	3.70	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-8.81	-5.85	-25.03	-14.33	--	--
Close Price ($)	75.25	47.70	121.85	62.29	--	--
High Price ($)	82.20	141.30	134.92	64.47	--	--
Low Price ($)	23.77	34.58	31.30	24.21	--	--
Market Cap ($ Cr)	3,806.15	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-08	Dec-07	Dec-06	Dec-05	Dec-04
Debt to Equity	--	0.01	0.00	0.01	--	--
Short term debt to equity ratio	0.01	0.00	0.00	0.00	--	--
Current Ratio	16.83	21.08	46.35	29.57	19.08	10.08
Quick Ratio	16.83	--	--	--	--	--
Interest Coverage	--	--	--	--	--	--

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-08	Dec-07	Dec-06	Dec-05	Dec-04
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	0.00	0.03	0.03	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.